EAEU Medical Device Registration Guide: Russia, Kazakhstan, Belarus, Armenia & Kyrgyzstan (2026–2028)

What Is the EAEU and Why It Matters for Medical Device Manufacturers

The Eurasian Economic Union (EAEU) is a single-market economic bloc comprising five member states: Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan. Together, these countries represent a medical device market estimated at $8–12 billion, with Russia alone accounting for roughly 70% of total EAEU device sales. The EAEU provides a framework for harmonized medical device registration that, once complete, allows a manufacturer to obtain a single Registration Certificate valid across all five member states.

The EAEU medical device regulatory framework was established by the Agreement on Common Principles and Rules for Circulation of Medical Devices, signed on December 23, 2014. The operational rules are set out in Decision No. 46 of the Eurasian Economic Commission (EEC) Council, dated February 12, 2016, which governs registration procedures, examination of safety and efficacy, and dossier requirements. Classification rules are defined in EEC Board Decision No. 173 (December 22, 2015).

The transition from national registration systems to the unified EAEU system has been repeatedly extended. The most recent extension, formalized by a Protocol signed on December 21, 2025, and adopted into Russian law through Government Resolution No. 2214 (December 30, 2025), set the following deadlines:

This means that as of 2026, manufacturers can choose between national registration (valid in a single country only) and EAEU registration (valid in all five member states). After January 1, 2028, all new registrations must follow the EAEU pathway.

Two Registration Pathways: National vs. EAEU

National Registration (Russia-Only)

National registration is conducted under Russian Government Decree No. 1684 (effective March 1, 2025, replacing the earlier Decree No. 1416). The resulting RZN Registration Certificate is valid indefinitely and covers only the Russian market. This pathway is administered by Roszdravnadzor (the Federal Service for Surveillance in Healthcare).

National registration may be the right choice for manufacturers who only plan to sell in Russia, need faster approval, or expect frequent product changes that would be cumbersome to coordinate across multiple EAEU member states.

EAEU (Sovereign Registration)

EAEU registration is conducted under Decision No. 46 of the EEC Council. The manufacturer selects one EAEU member state as the "Reference State" to conduct the primary expertise and review. At least one additional member state must be selected as a "State of Recognition." After the Reference State issues a positive decision, the other selected member states conduct a shorter recognition procedure (typically up to 30 calendar days each). The resulting Registration Certificate is issued indefinitely and is valid across all EAEU member states included in the application.

Key advantages of the EAEU pathway:

• Five markets, one registration: A single dossier, one set of tests, and one expertise process covers all selected member states.
• Cost efficiency: For manufacturers targeting two or more EAEU countries, the EAEU route is estimated to be 30–40% cheaper than pursuing separate national registrations.
• Future-proofing: After January 1, 2028, EAEU registration will be the only pathway available for new market entrants.

The EAEU pathway is strongly recommended for manufacturers with a long-term regional strategy or high-volume products that justify the investment in a single, multi-country dossier.

Medical Device Classification in the EAEU

EAEU classification follows a risk-based system defined in EEC Board Decision No. 173. The classification rules are broadly harmonized with the EU's risk-based approach but are applied under EAEU-specific criteria. Devices are classified into four risk classes for general medical devices, and separately for in vitro diagnostic (IVD) devices:

IVDs follow the same four-tier classification (I, IIa, IIb, III) under separate IVD-specific criteria.

Classification is based on several factors including duration of contact with the body, invasiveness, whether the device delivers medicines or energy, and whether it is used in vital organ systems. Each device is assigned to exactly one class.

EAEU Registration Process: Step-by-Step

Step 1: Strategy and Preparation (1–2 months)

The manufacturer (or their authorized representative, who must be a resident of an EAEU member state) determines the device classification, selects the Reference State and States of Recognition, and begins assembling the registration dossier.

A single authorized representative is appointed for all selected EAEU member states. Foreign manufacturers cannot submit applications directly — they must work through an EAEU-resident representative.

Step 2: Testing (2–6 months)

Depending on the risk class, the following tests are conducted in EAEU-accredited laboratories:

• Technical tests: Verification that the device meets applicable safety and performance standards. Conducted at accredited test centers within the EAEU.
• Toxicological studies: Assessment of biological safety, particularly for devices with patient contact.
• Clinical evaluation or clinical trials: Class I devices generally do not require clinical trials. Class IIa, IIb, and III devices require some form of clinical evaluation, which may range from literature-based analysis to full clinical investigations conducted at EAEU medical institutions.

Under the EAEU pathway, tests can be conducted in any EAEU member state — not only the Reference State. This flexibility can reduce costs and timelines.

Step 3: Dossier Compilation (1–2 months)

The registration dossier must follow the format prescribed in Annex 4 to Decision No. 46. Key documents include:

• Technical description and specifications (including drawings, diagrams, and materials)
• Risk analysis (aligned with ISO 14971 principles)
• Results of technical tests and toxicological studies
• Clinical evaluation report or clinical trial results
• Labeling and instructions for use (must be in the official language(s) of each target member state)
• Quality management system documentation
• Manufacturing information, including sterilization validation where applicable

All documents must be translated into Russian (for Russia as Reference State) and into the official languages of the other selected member states.

Step 4: Submission and Expertise (4–8 months)

The application is submitted to the competent authority of the Reference State. In Russia, this is Roszdravnadzor. The authority conducts a two-stage expertise:

1. Expertise of safety, quality, and efficacy: A detailed review of the dossier, test results, and clinical data. This is the longest stage.
2. Expertise of registration documents: Verification of labeling, IFU, and administrative documents.

For Class IIb and III devices, a manufacturing site inspection (GMP audit) is mandatory. For Class IIa sterile and Class IIa devices, it may be required. For Class I non-sterile, non-measuring devices, GMP inspection is voluntary. The inspection timeline (up to 90 calendar days) is not included in the formal registration timeline and can add 3–4 months to the overall process.

Step 5: Registration Certificate Issuance

Upon a positive decision from the Reference State, the Registration Certificate is issued. It is valid indefinitely.

Step 6: Mutual Recognition (up to 30 calendar days per state)

The States of Recognition conduct a shorter coordination procedure, reviewing the expert report from the Reference State and confirming (or challenging) the registration decision. In practice, most recognition procedures are completed within 30 days per state.

Step 7: Post-Market Surveillance

After registration, the manufacturer must comply with EAEU post-market surveillance requirements, including adverse event reporting, periodic safety updates, and field safety corrective actions. Each member state's competent authority conducts surveillance within its territory.

Government Fees (Russia as Reference State)

Fees are denominated in Russian rubles. The following rates apply under Russian national legislation (Government Decree No. 1684) and are also used as the reference for EAEU coordination fees:

These are government fees only. Total project costs including consulting, testing, translation, and travel for site inspections typically range from $30,000 to $120,000+ depending on device class and complexity.

Estimated Total Timelines

Timelines for national registration are generally faster because they involve a single authority. EAEU timelines are longer due to the coordination procedure across multiple member states, but the trade-off is access to five markets with one registration.

Key Regulatory Authorities

Practical Considerations for Foreign Manufacturers

Authorized Representative

Foreign manufacturers must appoint an authorized representative (AR) who is a legal entity registered in one of the EAEU member states. The AR is responsible for communicating with regulatory authorities, maintaining registration documentation, and coordinating post-market obligations. Under the EAEU pathway, a single AR can represent the manufacturer across all member states.

Selecting an experienced AR is critical. The AR holds significant legal responsibility, including for adverse event reporting and field safety corrective actions. Poor AR performance can delay registration or result in regulatory action.

Language Requirements

All registration documents must be submitted in the official language of the Reference State (Russian for Russia). Additionally, labeling and instructions for use must be provided in the official language(s) of each target member state. Russia and Belarus use Russian. Kazakhstan requires both Kazakh and Russian. Armenia requires Armenian. Kyrgyzstan requires Kyrgyz and Russian.

Translation costs can be substantial, particularly for complex devices with lengthy IFU documents. Budget $5,000–$15,000 for translation depending on document volume and language pairs.

Manufacturing Site Inspection

For Class IIb and III devices, an on-site GMP inspection by the Reference State's competent authority is mandatory. Russia increasingly requires on-site inspections rather than accepting ISO 13485 certificates alone — a significant change from the pre-2023 national procedure where a legalized ISO 13485 certificate was often sufficient. The inspection follows a format similar to an ISO 13485 audit but includes Russia-specific requirements under Government Order No. 136 (February 9, 2022), which governs manufacturing site inspections for medical devices.

Inspections typically take 2–3 days on-site, plus preparation and follow-up. Budget for travel, translation during the inspection, and corrective actions.

Clinical Evaluation

EAEU clinical evaluation requirements are more stringent than some manufacturers expect. While Class I devices can often rely on literature-based clinical evaluations, Class IIa and above typically require some form of clinical data generated within the EAEU or from recognized foreign sources. The acceptability of foreign clinical data is evaluated on a case-by-case basis and depends on whether the data is relevant to the EAEU patient population and clinical practice.

Comparing EAEU to Other Major Regulatory Systems

Common Pitfalls and How to Avoid Them

1. Underestimating timelines: The most common mistake is assuming EAEU registration takes 6 months. For Class IIb and III devices, 12–18 months is realistic. Start early, especially given the December 2027 deadline for national registrations.

2. Incomplete dossier preparation: EAEU authorities are strict about dossier completeness. Missing documents result in formal requests that pause the review clock. Conduct a thorough gap analysis before submission.

3. GMP inspection delays: On-site inspections for Class IIb/III devices can add 3–4 months and are subject to inspector availability. Schedule inspections early in the process.

4. Translation quality: Poor translations of technical documents, labeling, and IFU are a frequent source of expert queries and delays. Use translators with medical device regulatory experience.

5. Choosing national registration when EAEU makes more sense: If you plan to sell in two or more EAEU countries within 3 years, the EAEU pathway is almost always more cost-effective than separate national registrations, despite its longer initial timeline.

Key 2026–2028 Dates to Watch

Frequently Asked Questions

Can I still use my existing national registration certificate? Yes. National registration certificates issued before the transition deadline remain valid indefinitely. You can continue to sell under your existing certificate and make amendments to it until December 31, 2028.

Do I need separate registrations for each EAEU country? Not under the EAEU pathway. A single EAEU registration certificate is valid in all member states included in your application. Under the national pathway, you need a separate registration for each country.

Is ISO 13485 certification sufficient for EAEU registration? ISO 13485 certification is a prerequisite, but for Class IIb and III devices, an on-site GMP inspection by the EAEU competent authority is also required. Russia no longer accepts ISO 13485 certificates alone for these device classes.

How long does EAEU registration take? Typical timelines range from 9–15 months for Class I–IIa devices and 12–24 months for Class IIb–III devices. Complex implantable devices and novel technologies may take longer.

What happens if I miss the national registration deadline? After December 31, 2027, new registrations can only be submitted under the EAEU pathway. Existing national certificates remain valid, but you cannot initiate new national registrations.

Can clinical trials conducted outside the EAEU be accepted? Yes, foreign clinical data can be accepted, but the EAEU authority will evaluate its relevance to the local patient population and clinical practice. Some devices may require supplementary clinical data generated within the EAEU.